Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Functional multiomics of cellular therapy and immune checkpoint blockade therapy for solid tumors

ABSTRACT: Functional multiomics of cellular therapy and immune checkpoint blockade therapy for solid tumors

PROVIDER: PRJNA796389 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Functional multiomics of cellular therapy and immune checkpoint blockade therapy for solid tumors

Project description:Functional multiomics of cellular therapy and immune checkpoint blockade therapy for solid tumors

| PRJNA796418 | ENA

Resistance to Checkpoint Blockade Therapy Through Inactivation of Antigen Presentation

Project description:Resistance to Checkpoint Blockade Therapy Through Inactivation of Antigen Presentation

| PRJNA398303 | ENA

Molecular portraits of tumor mutational and micro-environmental sculpting by immune checkpoint blockade therapy

Project description:Immune checkpoint blockade (ICB) has demonstrated significant promise for the treatment of advanced malignancies. Anti-CTLA4 and ant-PD1 therapy can activate the immune system and result in durable control in diseases such as melanoma and non-small cell lung cancer.

2018-01-23 | GSE91061 | GEO

Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

Project description:Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

| PRJNA445759 | ENA

Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

Project description:Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

| PRJNA445758 | ENA

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

Project description:Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

| PRJNA476140 | ENA

RNA-seq analysis of isogenic mouse prostate cancer cell lines with distinct sensitivity to immune checkpoint therapy

Project description:Resistant to immune checkpoint blockade (ICB) therapy, especially in a few solid tumor types including advanced prostate cancer (PCa), represents a formidable clinical challenge. In this study, we developed a series of ICB-resistant PCa cell lines from an ICB-sensitive PCa cell line previously developed from the PB-Cre+ PtenL/L p53L/L Smad4L/L mouse model of metastatic PCa. These four cell lines were profiled with RNAseq.

2024-02-13 | GSE252986 | GEO

GutMicrobiota as Biomarker for Immune Checkpoint Blockade Therapy

Project description:Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

| PRJEB48780 | ENA

Protease dysregulation during response and resistance to immune checkpoint blockade therapy (RNA-seq)

Project description:Protease dysregulation during response and resistance to immune checkpoint blockade therapy (RNA-seq)

| PRJNA793230 | ENA

Protease dysregulation during response and resistance to immune checkpoint blockade therapy (RNA-seq)

Project description:Immune checkpoint blockade (ICB) therapy does not benefit the majority of treated patients, and those who respond to the therapy can become resistant to it. Here we report the design and performance of systemically administered activity sensors conjugated to anti-programmed cell death protein 1 (αPD1) antibodies for the monitoring of antitumour responses to ICB therapy. RNA sequencing analysis revealed that differential expression of tumour and immune proteases underpins ICB response and resistance. We then designed a library of mass-barcoded sensors that, when cleaved by proteases, are released into urine, where they can be detected by mass spectrometry. By using syngeneic mouse models of colorectal cancer, we show that random-forest classification trained on mass-spectrometry signatures can be used to detect early antitumour responses and to discriminate resistance to ICB therapy driven by loss-of-function mutations in either the B2m or Jak1 genes. Our data supports the use of activity-based biomarkers that leverage protease dysregulation for response assessment and classification of refractory tumours.

2022-02-15 | GSE192796 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data